MedTrace Logo

Effect of Niaspan on Cholesterol in Men

NCT00765284 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2011-06-30

No results posted yet for this study

Summary

To determine whether 8 weeks of Niaspan treatment increases cholesterol efflux in male subjects with low HDL-C cholesterol when compared to no treatment.

To determine whether 8 weeks of Niaspan treatment increases fecal cholesterol excretion when compared to no treatment.

To determine whether 8 weeks of Niaspan treatment increases the rate of global reverse cholesterol transport when compared to no treatment.

Conditions

  • HDL Cholesterol

Sponsors & Collaborators

  • KineMed

    lead INDUSTRY

Principal Investigators

  • Scott Turner, PhD · KineMed, Inc.

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00765284 on ClinicalTrials.gov